The generic name of Lenvatinib is Lenvatinib Mesylate Capsules, and cancer patients can obtain certain therapeutic effects only if the drug is used in accordance with the drug indication. Lenvatinib mesylate capsule is a kind of complex kinase receptor inhibitor drug, and the indication of this drug is unresectable hepatocellular carcinoma that has not received systemic systemic treatment before. Therefore, the drug can be used only when the drug indication is met, and the drug may not be effective in other cancer patients. ADVERSE REACTIONS: Relevant clinical studies have shown that the most common adverse drug reactions caused by Lenvatinib Mesylate Capsules mainly include hypertension, physical fatigue, diarrhea, decreased appetite, weight loss, arthralgia, myalgia, palmar-plantar erythema syndrome, proteinuria, dysphonia, bleeding events, hypothyroidism, nausea and so on. Contraindications: lactating women, hypersensitivity to any of the components contained in the drug need to be contraindicated. Precautions: Since the use of the drug can cause hypertension, an adverse reaction, patients should have their blood pressure well controlled before receiving treatment. Lenvatinib Mesylate capsules are administered orally and should be taken by the patient at a fixed point of time every day, either on an empty stomach or with food. Individuals should strictly regulate the use of Lenvatinib Mesylate capsules under the guidance of a physician, and some of the adverse reactions that occur after the use of the drug need to be promptly notified to the physician for disposal.